<DOC>
	<DOCNO>NCT01695200</DOCNO>
	<brief_summary>This 12-week open label trial evaluate whether omega-3 fatty acid effective reduce severity autism comorbidities .</brief_summary>
	<brief_title>Omega-3 Fatty Acids Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Between age 5 18 year old Diagnosed Autism , Asperger Syndrome , PDDNOS DSMIV criterion ; meet Autism Spectrum classification Autism Diagnostic Interview Revised ( ADIR ) Autism Diagnostic Observation Schedule ( ADOS ) Written parental consent participation Those current standardofcare treatment ASD Below 5 18 year old No formal diagnosis Autism , Asperger Syndrome PDDNOS Without write parental consent participation Those brain pathology serious head injury , epilepsy , etc . Those current standardofcare treatment ASD Those psychotic symptom , selfinjurious behaviour and/or suicidal tendency , history clinically significant medical condition screen attend doctor increase risk associate study participation Those type medication supplement change dose</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>